Petrylak, D. P., Sternberg, C. N., Drakaki, A., de Wit, R., Nishiyama, H., Necchi, A., Castellano, D., Bamias, A., Chi, K. N., van der Heijden, M. S., Matsubara, N., Hussain, S., Flechon, A., Alekseev, B. Y., Yu, E. Y., Walgren, R. A., Russo, F., Zimmermann, A. H., Bell-Mcguinn, K. M., & Powles, T. B. (n.d.). 865PDRANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results. Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100097077173.0x000031